PubRank

P D Delmas

Author PubWeight™ 319.41‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Vitamin D3 and calcium to prevent hip fractures in the elderly women. N Engl J Med 1992 9.86
2 Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 1999 9.71
3 European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 2008 5.27
4 Dietary supplementation in elderly patients with fractured neck of the femur. Lancet 1990 4.47
5 Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group. N Engl J Med 1998 4.38
6 Do we need to change the WHO definition of osteoporosis? Osteoporos Int 2000 3.35
7 Serum bone Gla-protein: a specific marker for bone formation in postmenopausal osteoporosis. Lancet 1984 2.85
8 Ultrasonographic heel measurements to predict hip fracture in elderly women: the EPIDOS prospective study. Lancet 1996 2.83
9 Current use of bisphosphonates in oncology. International Bone and Cancer Study Group. J Clin Oncol 1998 2.73
10 Interim report and recommendations of the World Health Organization Task-Force for Osteoporosis. Osteoporos Int 1999 2.70
11 Markers of bone resorption predict hip fracture in elderly women: the EPIDOS Prospective Study. J Bone Miner Res 1996 2.61
12 Effect of calcium and cholecalciferol treatment for three years on hip fractures in elderly women. BMJ 1994 2.61
13 Increased bone turnover in late postmenopausal women is a major determinant of osteoporosis. J Bone Miner Res 1996 2.59
14 The collagenolytic activity of cathepsin K is unique among mammalian proteinases. J Biol Chem 1998 2.48
15 Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment. J Clin Endocrinol Metab 1994 2.39
16 Effectiveness of bisphosphonates on nonvertebral and hip fractures in the first year of therapy: the risedronate and alendronate (REAL) cohort study. Osteoporos Int 2006 2.34
17 Biochemical markers of bone turnover, endogenous hormones and the risk of fractures in postmenopausal women: the OFELY study. J Bone Miner Res 2000 2.24
18 The role of collagen in bone strength. Osteoporos Int 2005 2.19
19 Cross sectional evaluation of biochemical markers of bone, cartilage, and synovial tissue metabolism in patients with knee osteoarthritis: relations with disease activity and joint damage. Ann Rheum Dis 2001 2.18
20 Insights into material and structural basis of bone fragility from diseases associated with fractures: how determinants of the biomechanical properties of bone are compromised by disease. Endocr Rev 2006 2.08
21 Undercarboxylated osteocalcin measured with a specific immunoassay predicts hip fracture in elderly women: the EPIDOS Study. J Clin Endocrinol Metab 1997 2.04
22 Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate. J Bone Miner Res 2003 1.96
23 Molecular basis and clinical use of biochemical markers of bone, cartilage, and synovium in joint diseases. Arthritis Rheum 2000 1.85
24 Measurement of bone mineral content of the lumbar spine by dual energy x-ray absorptiometry in normal children: correlations with growth parameters. J Clin Endocrinol Metab 1990 1.83
25 Serum undercarboxylated osteocalcin is a marker of the risk of hip fracture: a three year follow-up study. Bone 1996 1.80
26 Serum undercarboxylated osteocalcin is a marker of the risk of hip fracture in elderly women. J Clin Invest 1993 1.78
27 Exercise before puberty may confer residual benefits in bone density in adulthood: studies in active prepubertal and retired female gymnasts. J Bone Miner Res 1998 1.77
28 Ibandronate for the prevention of nonvertebral fractures: a pooled analysis of individual patient data. Osteoporos Int 2008 1.76
29 The effect of vitamin D supplementation on vitamin D status and parathyroid function in elderly subjects. J Clin Endocrinol Metab 1988 1.71
30 Long-term effects of intravenous pamidronate in fibrous dysplasia of bone. Lancet 1994 1.71
31 How hip and whole-body bone mineral density predict hip fracture in elderly women: the EPIDOS Prospective Study. Osteoporos Int 1998 1.70
32 Increase in serum bone gamma-carboxyglutamic acid protein with aging in women. Implications for the mechanism of age-related bone loss. J Clin Invest 1983 1.69
33 The type I collagen fragments ICTP and CTX reveal distinct enzymatic pathways of bone collagen degradation. J Bone Miner Res 2003 1.68
34 Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study. Ann Rheum Dis 2005 1.66
35 Urinary excretion of pyridinium crosslinks: a new marker of bone resorption in metabolic bone disease. Bone Miner 1990 1.62
36 The deleterious effects of low-dose corticosteroids on bone density in patients with polymyalgia rheumatica. Br J Rheumatol 1998 1.59
37 Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double-blind, placebo-controlled extension trial. Arthritis Rheum 2001 1.58
38 Glucocorticoid-induced inhibition of osteoblastic bone formation in ewes: a biochemical and histomorphometric study. Osteoporos Int 1993 1.58
39 Strontium ranelate: dose-dependent effects in established postmenopausal vertebral osteoporosis--a 2-year randomized placebo controlled trial. J Clin Endocrinol Metab 2002 1.57
40 Incidence of limb fracture across Europe: results from the European Prospective Osteoporosis Study (EPOS). Osteoporos Int 2002 1.56
41 Markers of bone turnover for the management of patients with bone metastases from prostate cancer. Br J Cancer 2000 1.56
42 Independent predictors of all osteoporosis-related fractures in healthy postmenopausal women: the OFELY study. Bone 2003 1.54
43 Healthy elderly French women living at home have secondary hyperparathyroidism and high bone turnover in winter. EPIDOS Study Group. J Clin Endocrinol Metab 1996 1.53
44 Biochemical markers of bone turnover: potential use in the investigation and management of postmenopausal osteoporosis. Osteoporos Int 2008 1.50
45 Alendronate treatment of the postmenopausal osteoporotic woman: effect of multiple dosages on bone mass and bone remodeling. Am J Med 1995 1.48
46 Prevention of early postmenopausal bone loss with cyclical etidronate therapy (a double-blind, placebo-controlled study and 1-year follow-up) J Clin Endocrinol Metab 1997 1.48
47 Serum and synovial fluid osteocalcin (bone gla protein) levels in joint disease. Br J Rheumatol 1989 1.48
48 Bisphosphonates alter trabecular bone collagen cross-linking and isomerization in beagle dog vertebra. Osteoporos Int 2007 1.47
49 Long-term effects of intravenous pamidronate in fibrous dysplasia of bone. J Bone Miner Res 1997 1.42
50 Apparent pre- and postmenopausal bone loss evaluated by DXA at different skeletal sites in women: the OFELY cohort. J Bone Miner Res 1997 1.42
51 Evidence for a dense and intimate innervation of the bone tissue, including glutamate-containing fibers. Bone 1999 1.41
52 Which screening strategy using BMD measurements would be most cost effective for hip fracture prevention in elderly women? A decision analysis based on a Markov model. Osteoporos Int 2006 1.41
53 Biochemical measurements of bone turnover in children and adolescents. Osteoporos Int 2000 1.41
54 Incorporation and distribution of strontium in bone. Bone 2001 1.40
55 Bisphosphonates inhibit prostate and breast carcinoma cell adhesion to unmineralized and mineralized bone extracellular matrices. Cancer Res 1997 1.39
56 Diagnosis and management of osteoporosis in postmenopausal women: clinical guidelines. International Committee for Osteoporosis Clinical Guidelines. Clin Ther 1999 1.35
57 Assessment of the serum levels of bone alkaline phosphatase with a new immunoradiometric assay in patients with metabolic bone disease. J Clin Endocrinol Metab 1993 1.34
58 Assessment of osteoclast number and function: application in the development of new and improved treatment modalities for bone diseases. Osteoporos Int 2006 1.33
59 Bioavailable estradiol may be an important determinant of osteoporosis in men: the MINOS study. J Clin Endocrinol Metab 2001 1.30
60 Effect of menopause and hormone replacement therapy on the urinary excretion of pyridinium cross-links. J Clin Endocrinol Metab 1991 1.30
61 Effectiveness of instant vertebral assessment to detect prevalent vertebral fracture. Osteoporos Int 2006 1.30
62 Low serum IGF-1 and occurrence of osteoporotic fractures in postmenopausal women. Lancet 2000 1.28
63 Associations of vitamin D status with bone mineral density, bone turnover, bone loss and fracture risk in healthy postmenopausal women. The OFELY study. Bone 2006 1.27
64 Effects of oral chondroitin sulfate on the progression of knee osteoarthritis: a pilot study. Osteoarthritis Cartilage 1998 1.26
65 The impact of osteoporosis on quality-of-life: the OFELY cohort. Bone 2002 1.26
66 Treatment of fibrous dysplasia of bone with intravenous pamidronate: long-term effectiveness and evaluation of predictors of response to treatment. Bone 2004 1.25
67 Increased risk of falls and increased bone resorption in elderly men with partial androgen deficiency: the MINOS study. J Clin Endocrinol Metab 2003 1.23
68 Glutamate receptors are expressed by bone cells and are involved in bone resorption. Bone 1998 1.23
69 Structural determinants of hip fracture in elderly women: re-analysis of the data from the EPIDOS study. Osteoporos Int 2005 1.22
70 Different morphometric and densitometric parameters predict cervical and trochanteric hip fracture: the EPIDOS Study. J Bone Miner Res 1997 1.22
71 The differing tempo of growth in bone size, mass, and density in girls is region-specific. J Clin Invest 1999 1.21
72 Body composition in appropriate and in small for gestational age infants. Acta Paediatr 1997 1.21
73 Six and twelve month changes in bone turnover are related to reduction in vertebral fracture risk during 3 years of raloxifene treatment in postmenopausal osteoporosis. Osteoporos Int 2001 1.20
74 Influence of mature adipocytes on osteoblast proliferation in human primary cocultures. Bone 2000 1.20
75 Prevalent vertebral deformity predicts incident hip though not distal forearm fracture: results from the European Prospective Osteoporosis Study. Osteoporos Int 2001 1.20
76 Markers of bone turnover predict postmenopausal forearm bone loss over 4 years: the OFELY study. J Bone Miner Res 1999 1.19
77 Biochemical indices of bone turnover and the assessment of fracture probability. Osteoporos Int 2002 1.19
78 Severity of vertebral fracture reflects deterioration of bone microarchitecture. Osteoporos Int 2006 1.18
79 Cross-sectional assessment of age-related bone loss in men: the MINOS study. Bone 2000 1.17
80 Expression of thrombospondin (TSP1) and its receptors (CD36 and CD51) in normal, hyperplastic, and neoplastic human breast. Cancer Res 1993 1.17
81 Long-term effects of raloxifene on bone mineral density, bone turnover, and serum lipid levels in early postmenopausal women: three-year data from 2 double-blind, randomized, placebo-controlled trials. Arch Intern Med 2000 1.17
82 Ultrasound discriminates patients with hip fracture equally well as dual energy X-ray absorptiometry and independently of bone mineral density. J Bone Miner Res 1995 1.16
83 Osteoprotegerin serum levels in men: correlation with age, estrogen, and testosterone status. J Clin Endocrinol Metab 2001 1.16
84 Collagen Ialpha1 Sp1 polymorphism, bone mass, and bone turnover in healthy French premenopausal women: the OFELY study. J Bone Miner Res 1998 1.13
85 Assessment of bone resorption with a new marker of collagen degradation in patients with metabolic bone disease. J Clin Endocrinol Metab 1994 1.12
86 Urinary type II collagen C-telopeptide levels are increased in patients with rapidly destructive hip osteoarthritis. Ann Rheum Dis 2003 1.12
87 Expression of Semaphorin-3A and its receptors in endochondral ossification: potential role in skeletal development and innervation. Dev Dyn 2005 1.11
88 Increased bone resorption in moderate smokers with low body weight: the Minos study. J Clin Endocrinol Metab 2002 1.11
89 Effect of renal function on plasma levels of bone Gla-protein. J Clin Endocrinol Metab 1983 1.11
90 Contribution of bone mineral density and bone turnover markers to the estimation of risk of osteoporotic fracture in postmenopausal women. J Musculoskelet Neuronal Interact 2004 1.10
91 Estrogen-dependent increase in bone turnover and bone loss in postmenopausal women with breast cancer treated with anastrozole. Prevention with bisphosphonates. Bone 2007 1.09
92 Serum undercarboxylated osteocalcin correlates with hip bone mineral density in elderly women. J Bone Miner Res 1994 1.09
93 Markers of bone turnover in bone metastases. Cancer 2000 1.09
94 Corticosteroid-induced bone loss in men. J Clin Endocrinol Metab 1998 1.09
95 New developments in biochemical markers for osteoporosis. Calcif Tissue Int 1996 1.08
96 Bone formation rate in older normal women: concurrent assessment with bone histomorphometry, calcium kinetics, and biochemical markers. J Clin Endocrinol Metab 1988 1.08
97 Abnormal serum bone Gla protein levels in multiple myeloma. Crucial role of bone formation and prognostic implications. Cancer 1990 1.07
98 Influence of remodeling on the mineralization of bone tissue. Osteoporos Int 2009 1.07
99 In osteoporotic women treated with strontium ranelate, strontium is located in bone formed during treatment with a maintained degree of mineralization. Osteoporos Int 2009 1.07
100 Bone microdamage: a clinical perspective. Osteoporos Int 2009 1.07
101 The role of mineralization and organic matrix in the microhardness of bone tissue from controls and osteoporotic patients. Bone 2008 1.07
102 Serum levels of type IIA procollagen amino terminal propeptide (PIIANP) are decreased in patients with knee osteoarthritis and rheumatoid arthritis. Osteoarthritis Cartilage 2004 1.06
103 Biochemical markers of bone turnover and prediction of hip bone loss in older women: the study of osteoporotic fractures. J Bone Miner Res 1999 1.05
104 Uncoupling of bone metabolism in rheumatoid arthritis patients with or without joint destruction: assessment with serum type I collagen breakdown products. Bone 1999 1.04
105 Longitudinal study of bone loss in pre- and perimenopausal women: evidence for bone loss in perimenopausal women. Osteoporos Int 2000 1.04
106 Markers of bone metabolism in postmenopausal women with rheumatoid arthritis. Effects of corticosteroids and hormone replacement therapy. Arthritis Rheum 1995 1.03
107 Bone sialoprotein stimulates in vitro bone resorption. Endocrinology 1996 1.03
108 Insufficiently dosed intravenous ibandronate injections are associated with suboptimal antifracture efficacy in postmenopausal osteoporosis. Bone 2004 1.03
109 Measurement of serum osteocalcin with a human-specific two-site immunoradiometric assay. J Bone Miner Res 1992 1.03
110 Assessment of bone turnover in postmenopausal osteoporosis by measurement of serum bone Gla-protein. J Lab Clin Med 1983 1.02
111 Measurement of bone degradation products in serum using antibodies reactive with an isomerized form of an 8 amino acid sequence of the C-telopeptide of type I collagen. J Bone Miner Res 1997 1.02
112 Additive antitumor activities of taxoids in combination with the bisphosphonate ibandronate against invasion and adhesion of human breast carcinoma cells to bone. Int J Cancer 1999 1.02
113 Racemization and isomerization of type I collagen C-telopeptides in human bone and soft tissues: assessment of tissue turnover. Biochem J 2000 1.02
114 How does antiresorptive therapy decrease the risk of fracture in women with osteoporosis? Bone 2000 1.02
115 Urinary CTX-II and glucosyl-galactosyl-pyridinoline are associated with the presence and severity of radiographic knee osteoarthritis in men. Ann Rheum Dis 2005 1.01
116 Circulating levels of vitamins K1 and K2 decreased in elderly women with hip fracture. J Bone Miner Res 1993 1.01
117 Cortical and trabecular bone distribution in the femoral neck in osteoporosis and osteoarthritis. Bone 2008 1.01
118 Decreased beta-isomerization of the C-terminal telopeptide of type I collagen alpha 1 chain in Paget's disease of bone. J Bone Miner Res 1997 1.01
119 Serum estradiol and sex hormone-binding globulin and the risk of hip fracture in elderly women: the EPIDOS study. J Bone Miner Res 2000 1.01
120 Vitamin D receptor gene polymorphisms are associated with the risk of fractures in postmenopausal women, independently of bone mineral density. J Clin Endocrinol Metab 2005 1.01
121 Insulin-like growth factor I is a determinant of hip bone mineral density in men less than 60 years of age: MINOS study. Calcif Tissue Int 2004 1.00
122 Bone loss in elderly men: increased endosteal bone loss and stable periosteal apposition. The prospective MINOS study. Osteoporos Int 2007 0.98
123 Ultrasound measurements on os calcis: precision and age-related changes in a normal female population. Osteoporos Int 1993 0.98
124 Osteocalcin induces chemotaxis, secretion of matrix proteins, and calcium-mediated intracellular signaling in human osteoclast-like cells. J Cell Biol 1994 0.98
125 Risk factors for hip fracture in women with high BMD: EPIDOS study. Osteoporos Int 2004 0.98
126 MMP and non-MMP-mediated release of aggrecan and its fragments from articular cartilage: a comparative study of three different aggrecan and glycosaminoglycan assays. Osteoarthritis Cartilage 2006 0.98
127 Markers of bone turnover in hyperthyroidism and the effects of treatment. J Clin Endocrinol Metab 1994 0.98
128 Cross-sectional evaluation of bone metabolism in men. J Bone Miner Res 2001 0.98
129 Dramatic decrease of innervation density in bone after ovariectomy. Endocrinology 2004 0.97
130 Bone loss after orthotopic liver transplantation. Am J Med 1994 0.97
131 Normal carboxylation of circulating osteocalcin (bone Gla-protein) in Paget's disease of bone. Bone Miner 1990 0.97
132 Role of sex steroids in the regulation of bone morphology in men. The MINOS study. Osteoporos Int 2004 0.96
133 Complex formation of human thrombospondin with osteonectin. Eur J Biochem 1988 0.96
134 Long term effects of dichloromethylene diphosphonate in Paget's disease of bone. J Clin Endocrinol Metab 1982 0.96
135 Evaluation of a fully automated serum assay for C-terminal cross-linking telopeptide of type I collagen in osteoporosis. Clin Chem 2001 0.96
136 Assessment of 10-year absolute fracture risk: a new paradigm with worldwide application. Osteoporos Int 2008 0.96
137 Dual energy x-ray absorptiometry measurement of bone mineral content in newborns: validation of the technique. Pediatr Res 1992 0.95
138 Biochemical markers of bone turnover. Applications for osteoporosis. Endocrinol Metab Clin North Am 1998 0.95
139 Genetic influence on bone turnover in postmenopausal twins. J Clin Endocrinol Metab 1996 0.95
140 Serum type I collagen breakdown product (serum CTX) predicts hip fracture risk in elderly women: the EPIDOS study. Bone 2000 0.95
141 Homocysteine and fracture risk in postmenopausal women: the OFELY study. Osteoporos Int 2007 0.94
142 Pachydermoperiostosis with gastric hypertrophy, anemia, and increased serum bone Gla-protein levels. Arch Dermatol 1988 0.94
143 Effect of oral monthly ibandronate on bone microarchitecture in women with osteopenia-a randomized placebo-controlled trial. Osteoporos Int 2012 0.94
144 Vitamin D receptor gene polymorphisms do not predict bone turnover and bone mass in healthy premenopausal women. J Bone Miner Res 1995 0.94
145 Characterization of immunoreactive forms of human osteocalcin generated in vivo and in vitro. J Bone Miner Res 1994 0.93
146 High bone turnover is associated with accelerated bone loss but not with increased fracture risk in men aged 50 and over: the prospective MINOS study. Ann Rheum Dis 2007 0.92
147 Long-term effects of dichloromethylene diphosphonate (CI2MDP) on skeletal lesions in multiple myeloma. Metab Bone Dis Relat Res 1982 0.92
148 Impairment of gamma carboxylation of circulating osteocalcin (bone gla protein) in elderly women. J Bone Miner Res 1991 0.92
149 The bisphosphonate zoledronate decreases type II collagen breakdown in patients with Paget's disease of bone. Bone 2001 0.92
150 Decorin inhibits cell migration through a process requiring its glycosaminoglycan side chain. J Cell Biochem 1999 0.92
151 Risedronate: clinical usage. Int J Clin Pract 2001 0.91
152 In vitro evaluation of dose-effects of ethanol on human osteoblastic cells. Bone Miner 1993 0.91
153 Lack of correlation between start codon polymorphism of the vitamin D receptor gene and bone mineral density in premenopausal French women: the OFELY study. J Bone Miner Res 1998 0.91
154 Automatic-interactive measurement of resorption cavities in transiliac bone biopsies and correlation with deoxypyridinoline. Bone 1995 0.91
155 Role of vitamin D and parathyroid hormone in the regulation of bone turnover and bone mass in men: the MINOS study. Calcif Tissue Int 2003 0.91
156 Semiquantitative evaluation of prevalent vertebral deformities in men and their relationship with osteoporosis: the MINOS study. Osteoporos Int 2001 0.90
157 Serum osteocalcin is increased in patients with osteomalacia: correlations with biochemical and histomorphometric findings. J Clin Endocrinol Metab 1992 0.90
158 Risedronate dosing before breakfast compared with dosing later in the day in women with postmenopausal osteoporosis. Osteoporos Int 2009 0.90
159 Simple and sensitive method for quantification of fluorescent enzymatic mature and senescent crosslinks of collagen in bone hydrolysate using single-column high performance liquid chromatography. J Chromatogr B Analyt Technol Biomed Life Sci 2008 0.90
160 Impairment of bone turnover in elderly women with hip fracture. Calcif Tissue Int 1993 0.90
161 Biochemical assessment of bone turnover and bone fragility in men. Osteoporos Int 2007 0.90
162 Efficacy and safety of ibandronate given by intravenous injection once every 3 months. Bone 2004 0.89
163 Trabecular and endocortical bone remodeling in postmenopausal osteoporosis: comparison with normal postmenopausal women. Osteoporos Int 1990 0.89
164 Plasma BGP: an indicator of spontaneous bone loss and of the effect of oestrogen treatment in postmenopausal women. Eur J Clin Invest 1988 0.89
165 Association between a functional interleukin-6 gene polymorphism and peak bone mineral density and postmenopausal bone loss in women: the OFELY study. Bone 2002 0.88
166 Diabetes during pregnancy does not alter whole body bone mineral content in infants. J Clin Endocrinol Metab 1997 0.88
167 Effects of a new selective estrogen receptor modulator (MDL 103,323) on cancellous and cortical bone in ovariectomized ewes: a biochemical, histomorphometric, and densitometric study. J Bone Miner Res 2001 0.88
168 Falls explain between-center differences in the incidence of limb fracture across Europe. Bone 2002 0.88
169 Serum bone Gla-protein compared to bone histomorphometry in endocrine diseases. Bone 1985 0.87
170 Biochemical markers of bone turnover in men. Calcif Tissue Int 2001 0.87
171 Selective attachment of osteoprogenitors to laminin. Bone 1999 0.87
172 Molecular identification of NMDA glutamate receptors expressed in bone cells. J Cell Biochem 2001 0.87
173 Bone mineral density of the hip measured with dual-energy X-ray absorptiometry in normal elderly women and in patients with hip fracture. Osteoporos Int 1991 0.87
174 Active NMDA glutamate receptors are expressed by mammalian osteoclasts. J Physiol 1999 0.86
175 Protein-S, a vitamin K-dependent protein, is a bone matrix component synthesized and secreted by osteoblasts. Endocrinology 1992 0.86
176 Different effects of bisphosphonate and estrogen therapy on free and peptide-bound bone cross-links excretion. J Bone Miner Res 1995 0.86
177 Dose effects on ewe bone remodeling of short-term sodium fluoride administration--a histomorphometric and biochemical study. Bone 1991 0.86
178 Urinary excretion of glucosyl-galactosyl pyridinoline: a specific biochemical marker of synovium degradation. Rheumatology (Oxford) 2001 0.86
179 Effects of infliximab therapy on biological markers of synovium activity and cartilage breakdown in patients with rheumatoid arthritis. Ann Rheum Dis 2008 0.86
180 Active bone turnover of the cortico-endosteal envelope in postmenopausal osteoporosis. J Clin Endocrinol Metab 1987 0.86
181 Age-related changes in Os calcis ultrasonic indices: a 2-year prospective study. Osteoporos Int 1995 0.86
182 Immunochemical studies of conformational alterations in bone gamma-carboxyglutamic acid containing protein. Biochemistry 1984 0.86
183 Localization of platelet osteonectin at the internal face of the alpha-granule membranes in platelets and megakaryocytes. Blood 1992 0.85
184 Geographical variations in hip fracture risk for women: strong effects hidden in standardised ratios. Osteoporos Int 2008 0.85
185 Vitamin D receptor gene polymorphisms are not related to bone turnover, rate of bone loss, and bone mass in postmenopausal women: the OFELY Study. J Bone Miner Res 1996 0.85
186 Isoform-specific attachment of osteoprogenitors to laminins: mapping to the short arms of laminin-1. Exp Cell Res 1999 0.85
187 Decreased bone turnover in oral contraceptive users. Bone 1995 0.85
188 Osteopenia and bone-remodeling abnormalities in warfarin-treated lambs. J Bone Miner Res 1993 0.85
189 Urinary pyridinium cross-links as markers of bone resorption in tumor-associated hypercalcemia. J Clin Endocrinol Metab 1992 0.85
190 Variation in vertebral height ratios in population studies. European Vertebral Osteoporosis Study Group. J Bone Miner Res 1994 0.85
191 Can we stop bone loss and prevent hip fractures in the elderly? Osteoporos Int 1994 0.84
192 Association between collagen cross-links and trabecular microarchitecture properties of human vertebral bone. Bone 2009 0.84
193 Do markers of bone resorption add to bone mineral density and ultrasonographic heel measurement for the prediction of hip fracture in elderly women? The EPIDOS prospective study. Osteoporos Int 1998 0.84
194 Bisphosphonates in the treatment of bone diseases. N Engl J Med 1996 0.84
195 The use of different dual X-ray absorptiometry brands in a multicenter clinical trial: consequences and limits. J Clin Densitom 1999 0.84
196 Effect of once-yearly zoledronic acid on the spine and hip as measured by quantitative computed tomography: results of the HORIZON Pivotal Fracture Trial. Osteoporos Int 2009 0.84
197 Immunological screening of SPARC/Osteonectin in nonmineralized tissues. Bone 1992 0.84
198 Serum osteocalcin increases during fracture healing in elderly women with hip fracture. Bone 1995 0.84
199 Identification of the noncollagenous proteins of bovine bone by two-dimensional gel electrophoresis. Calcif Tissue Int 1984 0.84
200 Effects of ibuprofen on molecular markers of cartilage and synovium turnover in patients with knee osteoarthritis. Ann Rheum Dis 2004 0.84
201 Biochemical markers of bone formation reflect endosteal bone loss in elderly men--MINOS study. Bone 2004 0.84
202 Effects of intranasal 17beta-estradiol on bone turnover and serum insulin-like growth factor I in postmenopausal women. J Clin Endocrinol Metab 1999 0.83
203 Ultrasound velocity measured at the proximal phalanges: precision and age-related changes in normal females. Rev Rhum Engl Ed 1996 0.83
204 Specific antagonists of NMDA receptors prevent osteoclast sealing zone formation required for bone resorption. Biochem Biophys Res Commun 2000 0.83
205 An in vitro model to test the contribution of advanced glycation end products to bone biomechanical properties. Bone 2007 0.83
206 The short-term effects of conjugated estrogen on bone turnover in older women. J Clin Endocrinol Metab 1994 0.83
207 Fluoride-induced bone changes in lambs during and after exposure to sodium fluoride. Osteoporos Int 1991 0.83
208 Thrombospondin binds to the surface of human osteosarcoma cells and mediates platelet-osteosarcoma cell interaction. Cancer Res 1991 0.83
209 A model to monitor the efficacy of alendronate treatment in women with osteoporosis using a biochemical marker of bone turnover. Bone 1999 0.83
210 Distribution of thrombospondin and integrin alpha V in DCIS, invasive ductal and lobular human breast carcinomas. Analysis by electron microscopy. Virchows Arch 1995 0.83
211 Serum bone-gla protein after fracture. Clin Orthop Relat Res 1990 0.82
212 Serum bone gamma carboxyglutamic acid-containing protein in primary hyperparathyroidism and in malignant hypercalcemia. Comparison with bone histomorphometry. J Clin Invest 1986 0.82
213 Measurement of urinary excretion of nonisomerized and beta-isomerized forms of type I collagen breakdown products to monitor the effects of the bisphosphonate zoledronate in Paget's disease. Arthritis Rheum 1998 0.82
214 Association of bone microarchitecture with parathyroid hormone concentration and calcium intake in men: the STRAMBO study. Eur J Endocrinol 2011 0.82
215 Insulin like growth factor I hormonal regulation by growth hormone and by 1,25(OH)2D3 and activity on human osteoblast-like cells in short-term cultures. Bone 1990 0.82
216 The effects of oral calcitonin on bone collagen maturation: implications for bone turnover and quality. Osteoporos Int 2008 0.82
217 Effectiveness of risedronate and alendronate on nonvertebral fractures: an observational study through 2 years of therapy. Osteoporos Int 2013 0.81
218 Bone mass at lumbar spine and tibia in young males--impact of physical fitness, exercise, and anthropometric parameters: a prospective study in a cohort of military recruits. Bone 1995 0.81
219 Thrombospondin (TSP1) mediates in vitro proliferation of human MG-63 osteoblastic cells induced by alpha-thrombin. FEBS Lett 1993 0.81
220 Platelets contribute to circulating levels of bone sialoprotein in human. J Bone Miner Res 1992 0.81
221 Influence of experimental conditions on osteoblast activity in human primary bone cell cultures. J Bone Miner Res 1990 0.81
222 Serum bone GLA-protein is not a sensitive marker of bone turnover in Paget's disease of bone. Calcif Tissue Int 1986 0.81
223 Radioimmunoassay for osteonectin. Concentrations in bone, nonmineralized tissues, and blood. J Bone Miner Res 1987 0.81
224 [Measurement of bone density in the wrist using X-ray absorptiometry: comparison with measurements of other sites]. Rev Rhum Ed Fr 1994 0.81
225 Adverse effects of a SERM (Levormeloxifene). Safety parameters and bone mineral density 12 months after treatment withdrawal. Maturitas 2003 0.81
226 Influence of anthropometric parameters on ultrasound measurements of Os calcis. Osteoporos Int 1995 0.80
227 Matrix delivery transdermal 17beta-estradiol for the prevention of bone loss in postmenopausal women. The International Study Group. Osteoporos Int 1999 0.80
228 Recommendations for the registration of agents for prevention and treatment of glucocorticoid-induced osteoporosis: an update from the Group for the Respect of Ethics and Excellence in Science. Osteoporos Int 2008 0.80
229 Reconstructing the skeleton with intermittent parathyroid hormone. Trends Endocrinol Metab 2001 0.80
230 What do we know about biochemical bone markers? Baillieres Clin Obstet Gynaecol 1991 0.80
231 Bone markers. Baillieres Clin Rheumatol 1997 0.80
232 Perinatal serum bone Gla-protein and vitamin D metabolites in preterm and fullterm neonates. J Clin Endocrinol Metab 1987 0.80
233 Serum bone Gla-protein in renal osteodystrophy: comparison with bone histomorphometry. J Clin Endocrinol Metab 1986 0.80
234 Comparative evaluation of markers of bone resorption in patients with breast cancer-induced osteolysis before and after bisphosphonate therapy. Br J Cancer 1997 0.79
235 FRAX® probabilities and risk of major osteoporotic fracture in France. Osteoporos Int 2011 0.79
236 Osteonectin is an alpha-granule component involved with thrombospondin in platelet aggregation. J Bone Miner Res 1991 0.79
237 Osteoporosis. Endocrinol Metab Clin North Am 1997 0.79
238 Dual-energy X-ray absorptiometry in early life. Horm Res 1997 0.79
239 An immunoassay for type I collagen alpha 1 helicoidal peptide 620-633, a new marker of bone resorption in osteoporosis. Bone 2003 0.79
240 LIF, but not IL-6, regulates osteoprogenitor differentiation in rat calvaria cell cultures: modulation by dexamethasone. J Bone Miner Res 1998 0.79
241 Launch of the bone and joint decade 2000-2010. Osteoporos Int 2000 0.78
242 Specific radioimmunoassay for ovine bone gla-protein (osteocalcin). Acta Endocrinol (Copenh) 1988 0.78
243 Risk factors for peripheral fractures vary by age in older men--the prospective MINOS study. Osteoporos Int 2010 0.78
244 [Biochemical markers of bone turnover : clinical usefulness in osteoporosis]. Ann Biol Clin (Paris) 1999 0.78
245 Efficacy of levormeloxifene in the prevention of postmenopausal bone loss and on the lipid profile compared to low dose hormone replacement therapy. J Clin Endocrinol Metab 2001 0.78
246 Beneficial effects of aminohexane diphosphonate in patients with Paget's disease of bone resistant to sodium etidronate. Am J Med 1987 0.78
247 Comparison of morphometric assessment of prevalent vertebral deformities in women using different reference data. Bone 2000 0.78
248 The growth-supportive effect of thrombospondin (TSP1) and the expression of TSP1 by human MG-63 osteoblastic cells are both inhibited by dexamethasone. FEBS Lett 1993 0.78
249 Serum osteocalcin (bone Gla-protein), an index of bone growth in lambs. Comparison with age-related histomorphometric changes. Bone 1991 0.78
250 [Osteocalcin (or bone gla-protein), a new biological marker for studying bone pathology]. Presse Med 1986 0.77
251 Degradation of subcutaneous implants of bone particles from normal and warfarin-treated rats. J Bone Miner Res 1995 0.77
252 Similar prevalence of vertebral fractures despite different approaches to define reference data. Bone 2003 0.77
253 [Optimal management of patients with stress fractures and the role of the orthopedic surgeon in reducing the risk of new fractures]. Rev Chir Orthop Reparatrice Appar Mot 2006 0.77
254 [Assay of cross-linking molecules of collagen (pyridinolines) in the study of the degradation of bone tissue and articular cartilage]. Pathol Biol (Paris) 1993 0.77
255 Characteristics of a two-site immunoradiometric assay for human skeletal alkaline phosphatase in serum. Clin Chem 1994 0.77
256 Is the predictive power of previous fractures for new spine and non-spine fractures associated with biochemical evidence of altered bone remodelling? The EPOS study. European Prospective Osteoporosis Study. Clin Chim Acta 2002 0.77
257 Nomegestrol acetate may enhance the skeletal effects of estradiol on biochemical markers of bone turnover in menopausal women after a 12-week treatment period. Climacteric 2005 0.77
258 Effects of moderate physical training on prednisone-induced protein wasting: a study of whole-body and bone protein metabolism. Metabolism 1988 0.77
259 [Osteoporosis. Epidemiology, etiology, diagnosis, prevention]. Rev Prat 1997 0.77
260 Intertissular variations in osteonectin: a monoclonal antibody directed to bone osteonectin shows reduced affinity for platelet osteonectin. J Bone Miner Res 1991 0.77
261 [Effects of weightlessness on phospho-calcium metabolism and its hormonal regulation in man during the 51 G Franco-American space flight]. Pathol Biol (Paris) 1988 0.77
262 Serum bone Gla protein: a marker of bone turnover in hyperthyroidism. J Clin Endocrinol Metab 1986 0.76
263 Increased vertebral bone density in heavy drinkers of mineral water rich in fluoride. Lancet 1989 0.76
264 Circulating levels of osteonectin in normal subjects and patients with thrombocytopenia. Bone Miner 1990 0.76
265 In vitro exposure to sodium fluoride does not modify activity or proliferation of human osteoblastic cells in primary cultures. J Bone Miner Res 1993 0.76
266 Thrombomodulin is synthesized by osteoblasts, stimulated by 1,25-(OH)2D3 and activates protein C at their cell membrane. Endocrinology 1993 0.76
267 Indicators of bone formation in weight lifters. Calcif Tissue Int 1995 0.76
268 Role of platelet membrane glycoproteins Ib/IX and IIb/IIIa, and of platelet alpha-granule proteins in platelet aggregation induced by human osteosarcoma cells. Cancer Res 1993 0.76
269 Detection and measurement of vitamins K1 and K2 in human cortical and trabecular bone. J Bone Miner Res 1993 0.76
270 Low-intensity electrical stimulation counteracts the effects of ovariectomy on bone tissue of rats: effects on bone microarchitecture, viability of osteocytes, and nitric oxide expression. Calcif Tissue Int 2009 0.76
271 Evidence that free gamma carboxyglutamic acid circulates in serum. Clin Chim Acta 1989 0.76
272 Validation of the bone Gla protein (osteocalcin) assay. J Bone Miner Res 1990 0.76
273 Localization of thrombospondin, CD36 and CD51 during prenatal development of the human mammary gland. Differentiation 1994 0.76
274 Assessment of urinary pyridinoline excretion with a specific enzyme-linked immunosorbent assay in normal adults and in metabolic bone diseases. Bone 1995 0.76
275 [Measurement of bone mineral content by quantitative digital radiography. First results in the lumbar vertebrae]. Presse Med 1989 0.75
276 Dual-energy X-ray absorptiometry of the spine in anteroposterior and lateral projections. Osteoporos Int 1994 0.75
277 Cross-sectional and longitudinal assessment of pre- and postmenopausal bone loss with a portable forearm X-ray device: the Ofely study. Bone 2000 0.75
278 Variability and response of urinary resorption markers to hormone replacement therapy. J Bone Miner Res 1999 0.75
279 Bone width is correlated positively with the upper to the lower segment ratio in elderly men--the MINOS study. Bone 2006 0.75
280 [Skeletal distribution and biological markers of Paget's disease]. Rev Prat 1989 0.75
281 Increased plasma free gamma carboxyglutamic acid levels during deep vein thrombosis and intravascular disseminated coagulation. Thromb Res 1994 0.75
282 [Menopause and bone metabolism]. Rev Prat 1984 0.75
283 [Biphosphonates in the treatment of osteolytic metastasis. Essential actions on hypercalcemia and important on lytic lesions]. Rev Prat 1993 0.75
284 A number of osteocalcin antisera recognize epitopes on proteins other than osteocalcin in cultured skin fibroblasts: implications for the identification of cells of the osteoblastic lineage in vitro. J Bone Miner Res 1994 0.75
285 [New treatments in osteoporosis]. Rev Med Interne 2004 0.75
286 Is nitric oxide a mediator of the effects of low-intensity electrical stimulation on bone in ovariectomized rats? Calcif Tissue Int 2010 0.75
287 Pamidronate (Aredia) and zoledronate: update on clinical results. Introduction. Br J Clin Pract Suppl 1996 0.75
288 Standardization of bone marker nomenclature. Clin Chem 2001 0.75
289 [Measurement of lumbar bone mineral density by biphoton absorptiometry. Methodology. Reproductibility. Normal values]. Pathol Biol (Paris) 1987 0.75
290 [Bone and hormones. Effects of growth hormone on bone tissue in adults]. Presse Med 1999 0.75
291 Serum-free gamma carboxyglutamic acid (free Gla) is a poor biochemical marker of bone resorption in early postmenopausal women. Bone 1991 0.75
292 [Increase of vertebral bone density in heavy drinkers of mineral water with a high fluoride content]. Presse Med 1989 0.75
293 Evaluation of urinary pyridinium crosslink excretion as a marker of bone resorption in the rat. J Bone Miner Res 1994 0.75
294 Measurement of serum bone gla-protein (BGP) in humans with an ovine BGP-based radioimmunoassay. Clin Chem 1990 0.75
295 Serum bone gla-protein compared to bone histomorphometry in hemodialyzed patients. Adv Exp Med Biol 1986 0.75
296 Clinical use of selective estrogen receptor modulators. Curr Opin Rheumatol 2001 0.75
297 [The menopause and bone metabolism]. Rev Fr Gynecol Obstet 1985 0.75
298 Androgens increase osteoblast-stimulating activity of human breast cancer cells in vitro. J Steroid Biochem 1986 0.75
299 Bone histomorphometry and serum bone gla-protein in the diagnosis of primary hyperparathyroidism. World J Surg 1986 0.75
300 Lateral dual-photon absorptiometry: a new technique to measure the bone mineral density at the lumbar spine. J Bone Miner Res 1990 0.75
301 Effects of ossein-hydroxyapatite compound on ewe bone remodeling: biochemical and histomorphometric study. Clin Rheumatol 1991 0.75
302 Editorial. J Musculoskelet Neuronal Interact 2005 0.75
303 [Bone and hormones. Estrogens and antiestrogens: action on osteoporosis]. Presse Med 1999 0.75
304 [Measurement of lumbar bone density by biphotonic absorptiometry. Contribution of a multidetector system]. Rev Rhum Mal Osteoartic 1990 0.75
305 Bone Gla: protein in blood derived directly from human bone tissue. Calcif Tissue Int 1989 0.75
306 Insulin-like growth factor-II increases plasma osteocalcin concentration in newborn lambs. Bone Miner 1992 0.75
307 [Comparison of two methods of evaluation of dietary calcium intake]. Presse Med 1993 0.75
308 Influence of ovariectomy on bone metabolism in very old rats. Calcif Tissue Int 1996 0.75
309 [Diphosphonates in the treatment of hypercalcemia]. Rev Med Interne 1984 0.75
310 Tertatolol-induced lupus. Arthritis Rheum 1988 0.75
311 Cloning and sequence analysis of bovine bone sialoprotein cDNA: conservation of acidic domains, tyrosine sulfation consensus repeats, and RGD cell attachment domain. J Bone Miner Res 1994 0.75
312 Urinary excretion of pyridinium cross-links in healthy women; the long-term effects of menopause and oestrogen/progesterone therapy. Clin Endocrinol (Oxf) 1994 0.75
313 [Role of osteoclasts in the physiopathological mechanisms of malignant osteolysis]. Bull Cancer 1993 0.75
314 [Myelomatous bone. Histomorphometric study and therapeutic effects]. Rev Rhum Mal Osteoartic 1984 0.75
315 Prevalence of vertebral deformities according to the diagnostic method. Rev Rhum Engl Ed 1998 0.75
316 Influence of vitamin D and retinoids on the gammacarboxylation of osteocalcin in human osteosarcoma MG63 cells. Bone 1996 0.75
317 [Role of diphosphonates in the therapy of osteolysis and malignant hypercalcemia]. Rev Rhum Mal Osteoartic 1984 0.75
318 Paradoxical acute hypercalcemic effect of salmon calcitonin in patients having Paget's disease of bone after treatment with dichloromethylene diphosphonate. Horm Metab Res 1984 0.75
319 [Comparative study of serum osteocalcin and of the histomorphometric evaluation of iliac biopsy in postmenopausal osteoporosis]. Rev Rhum Mal Osteoartic 1984 0.75
320 Response to parathyroid hormone and 1,25-dihydroxyvitamin D3 of bone-derived cells isolated from normal children and children with abnormalities in skeletal development. J Clin Endocrinol Metab 1986 0.75
321 [Lumbar vertebrae mineral content in women. Normal values obtained using quantitative digital radiography]. Rev Rhum Mal Osteoartic 1989 0.75
322 [Therapeutic strategies for osteoporosis]. Ann Med Interne (Paris) 2000 0.75
323 Use of dual-energy X-ray absorptiometry for the measurements of small quantities of mineral. Biol Neonate 1997 0.75
324 [Osteoarticular complications of organ transplantations]. Rev Prat 1994 0.75
325 How can we reduce the burden of osteoporosis? Baillieres Clin Rheumatol 1997 0.75
326 [Acceptability and tolerance of prednisolone metasulfobenzoate in orally dispersing tablet]. Presse Med 2001 0.75
327 Clinical synthesis meeting on osteoporosis. Lancet 1999 0.75
328 [Prevention of osteoporosis]. Rev Prat 1987 0.75
329 Comparison between radial bone mineral density measured by single photon absorptiometry and histomorphometric bone mass parameters measured on iliac crest biopsies. Clin Rheumatol 1990 0.75
330 Flutamide-induced methemoglobinemia. DICP 1991 0.75